Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update.
Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX13, a biosimilar of Ipilimumab, was approved by the FDA for a phase 1 clinical trial as a first-line treatment for unresectable hepatocellular carcinoma. This approval marks a significant step for the company in expanding its clinical trials internationally, potentially enhancing its market position in the oncology sector and providing new treatment options for various cancers.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development of biosimilars and innovative biologics. The company is involved in the pharmaceutical and healthcare industry, with a market focus on oncology treatments.
Average Trading Volume: 1,446,389
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.89B
Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.